-+ 0.00%
-+ 0.00%
-+ 0.00%
IMMIX BIOPHARMA ANNOUNCES 89% COMPLETE RESPONSE RATE AT INTERIM UPDATE ACROSS ALL NEXICART-2 PATIENTS, WITH MRD-NEGATIVITY INDICATING POTENTIAL TO REACH UP TO 98% COMPLETE RESPONSE RATE, SUPPORTING POTENTIAL BEST-IN-CLASS THERAPY FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS
Share

Please log in to view news

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending